MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare form of solid tumour that affects around 2,000 people in the US each year. The green ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback